Interleukin-18, more than a Th1 cytokine

Seminars in Immunology

Volumn 25, Issue 6, 2013, Pages 439-448

  Novick, Daniela ^a   Kim, Soohyun ^b   Kaplanski, Gilles ^c,d   Dinarello, Charles A ^e,f  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b Konkuk University   (South Korea)

^c AIX MARSEILLE UNIVERSITY   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; PROTEIN PRECURSOR;

CYTOKINE PRODUCTION; DISEASE SEVERITY; GAMMA DELTA T LYMPHOCYTE; HEART DISEASE; HEMOPHAGOCYTIC SYNDROME; HISTIOCYTOSIS; HYPERPHAGIA; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; MACROPHAGE ACTIVATION SYNDROME; METABOLIC SYNDROME X; NONHUMAN; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TRANSGENIC MOUSE; VIRUS INFECTION;

ANIMALS; AUTOIMMUNE DISEASES; CASPASE 1; HEART DISEASES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-18; KILLER CELLS, NATURAL; MACROPHAGE ACTIVATION SYNDROME; MICE; SHOCK, SEPTIC; TH1 CELLS;

EID: 84892867717     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2013.10.014     Document Type: Review

References (159)

1. Okamura H., Nagata K., Komatsu T., Tanimoto T., Nukata Y., Tanabe F., et al. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 1995, 63:3966-3972.
2. Boraschi D., Dinarello C.A. IL-18 in autoimmunity: review. Eur Cytokine Netw 2006, 17:224-252.
3. Dinarello C.A. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 2007, 27:98-114.
4. Tsutsui H., Nakanishi K. Immunotherapeutic applications of IL-18. Immunotherapy 2012, 4:1883-1894.
5. Puren A.J., Fantuzzi G., Dinarello C.A. Gene expression, synthesis and secretion of IL-1β and IL-18 are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci USA 1999, 96:2256-2261.
6. Fantuzzi G., Reed D.A., Dinarello C.A. IL-12-induced IFNγ is dependent on caspase-1 processing of the IL-18 precursor. J Clin Invest 1999, 104:761-767.
7. Siegmund B., Lehr H.A., Fantuzzi G., Dinarello C.A. IL-1beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A 2001, 98:13249-13254.
8. Bersudsky M., Luski L., Fishman D., White R.M., Ziv-Sokolovskaya N., Dotan S., et al. Non-redundant properties of IL-1alpha and IL-1beta during acute colon inflammation in mice. Gut 2013.
9. Siegmund B., Fantuzzi G., Rieder F., Gamboni-Robertson F., Lehr H.A., Hartmann G., et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN- and TNF-production. Am J Physiol Regul Integr Comp Physiol 2001, 281:R1264-R1270.
10. Tsutsui H., Kayagaki N., Kuida K., Nakano H., Hayashi N., Takeda K., et al. Caspase-1-independent Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 1999, 11:359-367.
11. Brydges S.D., Mueller J.L., McGeough M.D., Pena C.A., Misaghi A., Gandhi C., et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 2009, 30:875-887.
12. Brydges S.D., Broderick L., McGeough M.D., Pena C.A., Mueller J.L., Hoffman H.M. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J Clin Invest 2013, 10.1172/JCI71543.
13. Mazodier K., Marin V., Novick D., Farnarier C., Robitail S., Schleinitz N., et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005, 106:3483-3489.
14. Chiossone L., Audonnet S., Chetaille B., Chasson L., Farnarier C., Berda-Haddad Y., et al. Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein. Front Immunol 2012, 3:239.
15. Kahn P.J., Cron R.Q. Higher-dose anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol 2013, 40:743-744.
16. Kelly A., Ramanan A.V. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008, 4:615-620.
17. Loh N.K., Lucas M., Fernandez S., Prentice D. Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra. Intern Med J 2012, 42:1358-1362.
18. Pomerantz B.J., Reznikov L.L., Harken A.H., Dinarello C.A. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A 2001, 98:2871-2876.
19. Sugawara S., Uehara A., Nochi T., Yamaguchi T., Ueda H., Sugiyama A., et al. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J Immunol 2001, 167:6568-6575.
20. Bossaller L., Chiang P.I., Schmidt-Lauber C., Ganesan S., Kaiser W.J., Rathinam V.A., et al. Cutting edge: FAS (CD95) mediates noncanonical IL-1beta and IL-18 maturation via caspase-8 in an RIP3-independent manner. J Immunol 2012, 189:5508-5512.
21. Weber A., Wasiliew P., Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal 2010, 3:cm1.
22. Morel J.C., Park C.C., Woods J.M., Koch A.E. A novel role for interleukin-18 in adhesion molecule induction through NFkappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem 2001, 276:37069-53707.
23. Lee J.K., Kim S.H., Lewis E.C., Azam T., Reznikov L.L., Dinarello C.A. Differences in signaling pathways by IL-1beta and IL-18. Proc Natl Acad Sci U S A 2004, 101:8815-8820.
24. Kim S.H., Han S.Y., Azam T., Yoon D.Y., Dinarello C.A. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005, 22:131-142.
25. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Ann Rev Immunol 2001, 19:423-474.
26. Dahl C.A., Schall R.P., He H.L., Cairns J.S. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol 1992, 148:597-603.
27. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001, 12:53-72.
28. Bellora F., Castriconi R., Doni A., Cantoni C., Moretta L., Mantovani A., et al. M-CSF induces the expression of a membrane-bound form of IL-18 in a subset of human monocytes differentiating in vitro toward macrophages. Eur J Immunol 2012, 42:1618-1626.
29. Nakamura S., Otani T., Ijiri Y., Motoda R., Kurimoto M., Orita K. IFN-gamma-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J Immunol 2000, 164:3330-3336.
30. Sennello J.A., Fayad R., Pini M., Gove M.E., Ponemone V., Cabay R.J., et al. Interleukin-18, together with interleukin-12, induces severe acute pancreatitis in obese but not in nonobese leptin-deficient mice. Proc Natl Acad Sci U S A 2008, 105:8085-8090.
31. + Th17 cells. J Exp Med 2012, 209:1595-1609.
32. Joosten L.A. Excessive interleukin-1 signaling determines the development of Th1 and Th17 responses in chronic inflammation. Arthritis Rheum 2010, 62:320-322.
33. Sutton C., Brereton C., Keogh B., Mills K.H., Lavelle E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006, 203:1685-1691.
34. Sutton C.E., Lalor S.J., Sweeney C.M., Brereton C.F., Lavelle E.C., Mills K.H. Interleukin-1 and IL-23 induce innate IL-17 production from gamma-delta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-341.
35. Aksentijevich I., Masters S.L., Ferguson P.J., Dancey P., Frenkel J., van Royen-Kerkhoff A., et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009, 360:2426-2437.
36. Reddy S., Jia S., Geoffrey R., Lorier R., Suchi M., Broeckel U., et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009, 360:2438-2444.
37. Lalor S.J., Dungan L.S., Sutton C.E., Basdeo S.A., Fletcher J.M., Mills K.H. Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gamma-delta and CD4 T cells that mediate autoimmunity. J Immunol 2011, 186:5738-5748.
38. Vidal-Vanaclocha F., Fantuzzi G., Mendoza L., Fuentes A.M., Anasagasti M.J., Martin J., et al. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci U S A 2000, 97:734-739.
39. Tsutsui H., Matsui K., Okamura H., Nakanishi K. Pathophysiological roles of interleukin-18 in inflammatory liver diseases. Immunol Rev 2000, 174:192-209.
40. Gatti S., Beck J., Fantuzzi G., Bartfai T., Dinarello C.A. Effect of interleukin-18 on mouse core body temperature. Am J Physiol Regul Integr Comp Physiol 2002, 282:R702-R709.
41. Li S., Goorha S., Ballou L.R., Blatteis C.M. Intracerebroventricular interleukin-6, macrophage inflammatory protein-1 beta and IL-18: pyrogenic and PGE(2)-mediated?. Brain Res 2003, 992:76-84.
42. Robertson M.J., Mier J.W., Logan T., Atkins M., Koon H., Koch K.M., et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 2006, 12:4265-4273.
43. Reznikov L.L., Kim S.H., Westcott J.Y., Frishman J., Fantuzzi G., Novick D., et al. IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. Proc Natl Acad Sci U S A 2000, 97:2174-2179.
44. Tak P.P., Bacchi M., Bertolino M. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet 2006, 31:109-116.
45. Joosten L.A., van De Loo F.A., Lubberts E., Helsen M.M., Netea M.G., van Der Meer J.W., et al. An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J Immunol 2000, 165:6553-6558.
46. Carrascal M.T., Mendoza L., Valcarcel M., Salado C., Egilegor E., Telleria N., et al. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 2003, 63:491-497.
47. ten Hove T., van Montfrans C., Peppelenbosch M.P., van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50:206-211.
48. Sandborn W.J., Feagan B.G., Fedorak R.N., Scherl E., Fleisher M.R., Katz S., et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008, 135:1130-1141.
49. Mannon P.J., Fuss I.J., Mayer L., Elson C.O., Sandborn W.J., Present D., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004, 351:2069-2079.
50. Pizarro T.T., Michie M.H., Bentz M., Woraratanadharm J., Smith M.F., Foley E., et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999, 162:6829-6835.
51. Monteleone G., Trapasso F., Parrello T., Biancone L., Stella A., Iuliano R., et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999, 163:143-147.
52. Ten Hove T., Corbaz A., Amitai H., Aloni S., Belzer I., Graber P., et al. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 2001, 121:1372-1379.
53. Siegmund B. Interleukin-1b converting enzyme and intestinal inflammation. Biochem Pharmacol 2002, 7273:1-8.
54. Bauer C., Duewell P., Mayer C., Lehr H.A., Fitzgerald K.A., Dauer M., et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010, 59:1192-1199.
55. Bauer C., Loher F., Dauer M., Mayer C., Lehr H.A., Schonharting M., et al. The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-alpha mRNA expression. Dig Dis Sci 2007, 52:1642-1652.
56. Loher F., Bauer C., Landauer N., Schmall K., Siegmund B., Lehr H.A., et al. The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther 2004, 308:583-590.
57. Banerjee S., Bond J.S. Prointerleukin-18 is activated by meprin beta in vitro and in vivo in intestinal inflammation. J Biol Chem 2008, 283:31371-73137.
58. Allen I.C., TeKippe E.M., Woodford R.M., Uronis J.M., Holl E.K., Rogers A.B., et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010, 207:1045-1056.
59. Dupaul-Chicoine J., Yeretssian G., Doiron K., Bergstrom K.S., McIntire C.R., LeBlanc P.M., et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010, 32:367-378.
60. Hirota S.A., Ng J., Lueng A., Khajah M., Parhar K., Li Y., et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 2011, 17:1359-1372.
61. Elinav E., Strowig T., Kau A.L., Henao-Mejia J., Thaiss C.A., Booth C.J., et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011, 145:745-757.
62. Chen C.J., Kono H., Golenbock D., Reed G., Akira S., Rock K.L. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007, 13:851-856.
63. Siegmund B. Interleukin-18 in intestinal inflammation: friend and foe?. Immunity 2010, 32:300-302.
64. Netea M.G., Joosten L.A., Lewis E., Jensen D.R., Voshol P.J., Kullberg B.J., et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 2006, 12:650-656.
65. Zorrilla E.P., Sanchez-Alavez M., Sugama S., Brennan M., Fernandez R., Bartfai T., et al. Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc Natl Acad Sci U S A 2007, 104:11097-21110.
66. Abbate A., Van Tassell B.W., Seropian I.M., Toldo S., Robati R., Varma A., et al. Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail 2010, 12:319-322.
67. Abbate A., Salloum F.N., Vecile E., Das A., Hoke N.N., Straino S., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008, 117:2670-2683.
68. Abbate A. The heart on fire: inflammasome and cardiomyopathy. Exp Physiol 2013, 98:385.
69. Van Tassell B.W., Arena R., Toldo S., Mezzaroma E., Azam T., Seropian I.M., et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS ONE 2012, 7:e33438.
70. Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1 beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011, 162:597-605.
71. Mallat Z., Heymes C., Corbaz A., Logeart D., Alouani S., Cohen-Solal A., et al. Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEB J 2004, 18:1752-1754.
72. Platis A., Yu Q., Moore D., Khojeini E., Tsau P., Larson D. The effect of daily administration of IL-18 on cardiac structure and function. Perfusion 2008, 23:237-242.
73. Woldbaek P.R., Sande J.B., Stromme T.A., Lunde P.K., Djurovic S., Lyberg T., et al. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol 2005, 289:H708-H714.
74. Raeburn C.D., Dinarello C.A., Zimmerman M.A., Calkins C.M., Pomerantz B.J., McIntyre R.C., et al. Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol 2002, 283:H650-H657.
75. Doyle S.L., Campbell M., Ozaki E., Salomon R.G., Mori A., Kenna P.F., et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med 2012, 18:791-798.
76. Novick D., Kim S.-H., Fantuzzi G., Reznikov L., Dinarello C.A., Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999, 10:127-136.
77. Novick D., Schwartsburd B., Pinkus R., Suissa D., Belzer I., Sthoeger Z., et al. A novel IL-18BP ELISA shows elevated serum il-18BP in sepsis and extensive decrease of free IL-18. Cytokine 2001, 14:334-342.
78. Novick D., Elbirt D., Dinarello C.A., Rubinstein M., Sthoeger Z.M. Interleukin-18 binding protein in the sera of patients with Wegener's granulomatosis. J Clin Immunol 2009, 29:38-45.
79. Novick D., Elbirt D., Miller G., Dinarello C.A., Rubinstein M., Sthoeger Z.M. High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. J Autoimmun 2011, 34:121-126.
80. Bufler P., Azam T., Gamboni-Robertson F., Reznikov L.L., Kumar S., Dinarello C.A., et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci U S A 2002, 99:13723-81372.
81. Dinarello C., Arend W., Sims J., Smith D., Blumberg H., O'Neill L., et al. IL-1 family nomenclature. Nat Immunol 2010, 11:973.
82. McNamee E.N., Masterson J.C., Jedlicka P., McManus M., Grenz A., Collins C.B., et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A 2011, 108:16711-61671.
83. Banda N.K., Vondracek A., Kraus D., Dinarello C.A., Kim S.H., Bendele A., et al. Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J Immunol 2003, 170:2100-2105.
84. Muhl H., Kampfer H., Bosmann M., Frank S., Radeke H., Pfeilschifter J. Interferon-gamma mediates gene expression of IL-18 binding protein in nonleukocytic cells. Biochem Biophys Res Commun 2000, 267:960-963.
85. Hurgin V., Novick D., Rubinstein M. The promoter of IL-18 binding protein: activation by an IFN-gamma-induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein beta. Proc Natl Acad Sci U S A 2002, 99:16957-21696.
86. Kaser A., Novick D., Rubinstein M., Siegmund B., Enrich B., Koch R.O., et al. Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol 2002, 129:332-338.
87. Ludwiczek O., Kaser A., Novick D., Dinarello C.A., Rubinstein M., Vogel W., et al. Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J Clin Immunol 2002, 22:331-337.
88. Wittmann M., Bachmann M., Doble R., Pfeilschifter J., Werfel T., Mühl H. IL-27 regulates IL-18 binding protein in skin resident cells. PLoS ONE 2012, 7:e38751.
89. Xiang Y., Moss B. Correspondence of the functional epitopes of poxvirus and human interleukin-18-binding proteins. J Virol 2001, 75:9947-9954.
90. Grom A.A. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities?. Curr Opin Rheumatol 2003, 15:587-590.
91. Grom A.A., Mellins E.D. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol 2011, 22:561-566.
92. Grom A.A., Villanueva J., Lee S., Goldmuntz E.A., Passo M.H., Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003, 142:292-296.
93. Janka G.E. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med 2012, 63:233-246.
94. Ogilvie E.M., Khan A., Hubank M., Kellam P., Woo P. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007, 56:1954-1965.
95. Sumegi J., Barnes M.G., Nestheide S.V., Molleran-Lee S., Villanueva J., Zhang K., et al. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood 2011, 117:e151-e160.
96. Maeno N., Takei S., Imanaka H., Yamamoto K., Kuriwaki K., Kawano Y., et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum 2004, 50:1935-1938.
97. Emmenegger U., Reimers A., Frey U., Fux C., Bihl F., Semela D., et al. Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly 2002, 132:230-236.
98. Nold-Petry C.A., Lehrnbecher T., Jarisch A., Schwabe D., Pfeilschifter J.M., Muhl H., et al. Failure of interferon gamma to induce the anti-inflammatory interleukin 18 binding protein in familial hemophagocytosis. PLoS One 2010, 5:e8663.
99. Honda K., Ohga S., Takada H., Nomura A., Ohshima K., Kinukawa N., et al. Neuron-specific enolase in hemophagocytic lymphohistiocytosis: a potential indicator for macrophage activation?. Int J Hematol 2000, 72:55-60.
100. Wada T., Muraoka M., Yokoyama T., Toma T., Kanegane H., Yachie A. Cytokine profiles in children with primary Epstein-Barr virus infection. Pediatr Blood Cancer 2013, 60:E46-E48.
101. Fitzgerald A.A., Leclercq S.A., Yan A., Homik J.E., Dinarello C.A. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005, 52:1794-1803.
102. Larroche C., Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmunity Rev 2004, 3:69-75.
103. Favilli F., Anzilotti C., Martinelli L., Quattroni P., De Martino S., Pratesi F., et al. IL-18 activity in systemic lupus erythematosus. Ann N Y Acad Sci 2009, 1173:301-309.
104. Sivakumar P.V., Westrich G.M., Kanaly S., Garka K., Born T.L., Derry J.M., et al. Interleukin-18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin-18 attenuates intestinal damage. Gut 2002, 50:812-820.
105. Wirtz S., Becker C., Blumberg R., Galle P.R., Neurath M.F. Treatment of T Cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J Immunol 2002, 168:411-420.
106. Plater-Zyberk C., Joosten L.A., Helsen M.M., Sattonnet-Roche P., Siegfried C., Alouani S., et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001, 108:1825-1832.
107. Smeets R.L., van de Loo F.A., Arntz O.J., Bennink M.B., Joosten L.A., van den Berg W.B. Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther 2003, 10:1004-1011.
108. Leng J., Yao H., Shen J., Wang K., Zhuo G., Wang Z. Co-expression of IL-18 binding protein and IL-4 regulates Th1/Th2 cytokine response in murine collagen-induced arthritis. Acta Biochim Biophys Sin 2008, 40:116-124.
109. Wei X.Q., Leung B.P., Arthur H.M., McInnes I.B., Liew F.Y. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 2001, 166:517-521.
110. Buch M.H., Bingham S.J., Seto Y., McGonagle D., Bejarano V., White J., et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum 2004, 50:725-728.
111. Bossu P., Neumann D., Del Giudice E., Ciaramella A., Gloaguen I., Fantuzzi G., et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci U S A 2003, 100:14181-14186.
112. Maecker H.T., Hansen G., Walter D.M., DeKruyff R.H., Levy S., Umetsu D.T. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J Immunol 2001, 166:959-965.
113. Im S.H., Barchan D., Maiti P.K., Raveh L., Souroujon M.C., Fuchs S. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J 2001, 15:2140-2148.
114. Furlan R., Martino G., Galbiati F., Poliani P.L., Smiroldo S., Bergami A., et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 1999, 163:2403-2409.
115. Faggioni R., Jones-Carson J., Reed D.A., Dinarello C.A., Feingold K.R., Grunfeld C., et al. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci U S A 2000, 97:2367-2372.
116. Faggioni R., Cattley R.C., Guo J., Flores S., Brown H., Qi M., et al. IL-18-binding protein protects against lipopolysaccharide-induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice. J Immunol 2001, 167:5913-5920.
117. Fantuzzi G., Banda N.K., Guthridge C., Vondracek A., Kim S.H., Siegmund B., et al. Generation and characterization of mice transgenic for human IL-18-binding protein isoform A. J Leukoc Biol 2003, 74:889-896.
118. Shao X., Qian Y., Xu C., Hong B., Xu W., Shen L., et al. The protective effect of intrasplenic transplantation of Ad-IL-18BP/IL-4 gene-modified fetal hepatocytes on ConA-induced hepatitis in mice. PLoS ONE 2013, 8:e58836.
119. Okamura H., Tsutsui H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., et al. Cloning of a new cytokine that induces interferon-γ. Nature 1995, 378:88-91.
120. Netea M.G., Fantuzzi G., Kullberg B.J., Stuyt R.J., Pulido E.J., McIntyre R.C., et al. Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J Immunol 2000, 164:2644-2649.
121. Yellayi S., Braun S., Domingues H.G., Kityatana N., Murali R., Johnson R.P., et al. Cloning and characterization of rhesus IL-18 binding protein, a natural antagonist to IL-18. Cytokine 2010, 51:232-239.
122. Cao Q., Cai W., Niu G., He L., Chen X. Multimodality imaging of IL-18 - binding protein-Fc therapy of experimental lung metastasis. Clin Cancer Res 2008, 14:6137-6145.
123. Takeuchi D., Yoshidome H., Kato A., Ito H., Kimura F., Shimizu H., et al. Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice. Hepatology 2004, 39:699-710.
124. Melnikov V.Y., Ecder T., Fantuzzi G., Siegmund B., Lucia M.S., Dinarello C.A., et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest 2001, 107:1145-1152.
125. Wang M., Tan J., Wang Y., Meldrum K.K., Dinarello C.A., Meldrum D.R. IL-18 binding protein-expressing mesenchymal stem cells improve myocardial protection after ischemia or infarction. Proc Natl Acad Sci U S A 2009, 106:17499-17504.
126. Mallat Z., Corbaz A., Scoazec A., Graber P., Alouani S., Esposito B., et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001, 89:E41-E45.
127. Kawashima M., Miossec P. Heterogeneity of response of rheumatoid synovium cell subsets to interleukin-18 in relation to differential interleukin-18 receptor expression. Arthritis Rheum 2003, 48:631-637.
128. Ono S., Obara H., Takayanagi A., Tanabe M., Kawachi S., Itano O., et al. Suppressive effects of interleukin-18 on liver function in rat liver allografts. J Surg Res 2012, 176:293-300.
129. Siegmund B., Sennello J.A., Lehr H.A., Senaldi G., Dinarello C.A., Fantuzzi G. Interferon regulatory factor-1 as a protective gene in intestinal inflammation: role of TCR gamma delta T cells and interleukin-18-binding protein. Eur J Immunol 2004, 34:2356-2364.
130. Sifringer M., Stefovska V., Endesfelder S., Stahel P.F., Genz K., Dzietko M., et al. Activation of caspase-1 dependent interleukins in developmental brain trauma. Neurobiol Dis 2007, 25:614-622.
131. Yatsiv I., Morganti-Kossmann M.C., Perez D., Dinarello C.A., Novick D., Rubinstein M., et al. Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury. J Cereb Blood Flow Metab 2002, 22:971-978.
132. Stuyt R.J., Kim S.H., Reznikov L.L., Fantuzzi G., Novick D., Rubinstein M., et al. Regulation of Staphylococcus epidermidis-induced IFN-gamma in whole human blood: the role of endogenous IL-18, IL-12, IL-1, and TNF. Cytokine 2003, 21:65-73.
133. Wyburn K., Wu H., Chen G., Yin J., Eris J., Chadban S. Interleukin-18 affects local cytokine expression but does not impact on the development of kidney allograft rejection. Am J Transplant 2006, 6:2612-2621.
134. Hoshino K., Tsutsui H., Kawai T., Takeda K., Nakanishi K., Takeda Y., et al. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol 1999, 162:5041-5044.
135. Okamoto M., Kato S., Oizumi K., Kinoshita M., Inoue Y., Hoshino K., et al. Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood 2002, 99:1289-1298.
136. Itoi H., Fujimori Y., Tsutsui H., Matsui K., Sugihara A., Terada N., et al. Involvement of interleukin-18 in acute graft-versus-host disease in mice. Transplantation 2004, 78:1245-1250.
137. Kinoshita K., Yamagata T., Nozaki Y., Sugiyama M., Ikoma S., Funauchi M., et al. Blockade of IL-18 receptor signaling delays the onset of autoimmune disease in MRL-Faslpr mice. J Immunol 2004, 173:5312-5318.
138. Cheung H., Chen N.J., Cao Z., Ono N., Ohashi P.S., Yeh W.C. Accessory protein-like is essential for IL-18-mediated signaling. J Immunol 2005, 174:5351-5357.
139. Takagi H., Kanai T., Okazawa A., Kishi Y., Sato T., Takaishi H., et al. Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. Scand J Gastroenterol 2003, 38:837-844.
140. Murray D.R., Mummidi S., Valente A.J., Yoshida T., Somanna N.K., Delafontaine P., et al. Beta 2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo. J Mol Cell Cardiol 2012, 52:206-218.
141. He Z., Lu L., Altmann C., Hoke T.S., Ljubanovic D., Jani A., et al. Interleukin-18 binding protein transgenic mice are protected against ischemic acute kidney injury. Am J Physiol Renal Physiol 2008, 295:F1414-F1421.
142. Lewis E.C., Dinarello C.A. Responses of IL-18- and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor. Proc Natl Acad Sci U S A 2006, 103:16852-16857.
143. Emmanuilidis K., Weighardt H., Matevossian E., Heidecke C.D., Ulm K., Bartels H., et al. Differential regulation of systemic IL-18 and IL-12 release during postoperative sepsis: high serum IL-18 as an early predictive indicator of lethal outcome. Shock (Augusta, Ga.) 2002, 18:301-305.
144. Mommsen P., Frink M., Pape H.C., van Griensven M., Probst C., Gaulke R., et al. Elevated systemic IL-18 and neopterin levels are associated with posttraumatic complications among patients with multiple injuries: a prospective cohort study. Injury 2009, 40:528-534.
145. Palladino I., Salani F., Ciaramella A., Rubino I.A., Caltagirone C., Fagioli S., et al. Elevated levels of circulating IL-18BP and perturbed regulation of IL-18 in schizophrenia. J Neuroinflamm 2012, 9:206.
146. Haas S.L., Abbatista M., Brade J., Singer M.V., Bocker U. Interleukin-18 serum levels in inflammatory bowel diseases: correlation with disease activity and inflammatory markers. Swiss Med Wkly 2009, 139:140-145.
147. Ludwiczek O., Kaser A., Novick D., Dinarello C.A., Rubinstein M., Tilg H. Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. Eur Cytokine Netw 2005, 16:27-33.
148. Bokarewa M., Hultgren O. Is interleukin-18 useful for monitoring rheumatoid arthritis?. Scand J Rheumatol 2005, 34:433-436.
149. Jelusic M., Lukic I.K., Tambic-Bukovac L., Dubravcic K., Malcic I., Rudan I., et al. Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. Clin Rheumatol 2007, 26:1332-1334.
150. Kawashima M., Yamamura M., Taniai M., Yamauchi H., Tanimoto T., Kurimoto M., et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001, 44:550-560.
151. Blankenberg S., Luc G., Ducimetiere P., Arveiler D., Ferrieres J., Amouyel P., et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003, 108:2453-2459.
152. Narins C.R., Lin D.A., Burton P.B., Jin Z.G., Berk B.C. Interleukin-18 and interleukin-18 binding protein levels before and after percutaneous coronary intervention in patients with and without recent myocardial infarction. Am J Cardiol 2004, 94:1285-1287.
153. Thompson S.R., Novick D., Stock C.J., Sanders J., Brull D., Cooper J., et al. Free interleukin (IL)-18 levels, and the impact of IL18 and IL18BP genetic variation, in CHD patients and healthy men. Arterioscler Thromb Vasc Biol 2007, 27:2743-2749.
154. Troseid M., Seljeflot I., Arnesen H. The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol 2010, 9:11.
155. Parikh C.R., Abraham E., Ancukiewicz M., Edelstein C.L. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the ICU. J Am Soc Nephrol 2005, 16:3046-3052.
156. Vaidya V.S., Waikar S.S., Ferguson M.A., Collings F.B., Sunderland K., Gioules C., et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 2008, 1:200-208.
157. Parikh C.R., Mishra J., Thiessen-Philbrook H., Dursun B., Ma Q., Kelly C., et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 2006, 70:199-203.
158. Sirota J.C., Walcher A., Faubel S., Jani A., McFann K., Devarajan P., et al. Urine IL-18, NGAL, IL-8 and serum IL-8 are biomarkers of acute kidney injury following liver transplantation. BMC Nephrol 2013, 14:17.
159. Kim S.H., Eisenstein M., Reznikov L., Fantuzzi G., Novick D., Rubinstein M., et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A. 2000, 97:1190-1195.